当前位置：
X-MOL 学术
›
Electroanalysis
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Validated Voltammetric Method for the Simultaneous Determination of Anti‐diabetic Drugs, Linagliptin and Empagliflozin in Bulk, Pharmaceutical Dosage Forms and Biological Fluids
Electroanalysis ( IF 2.7 ) Pub Date : 2020-04-08 , DOI: 10.1002/elan.202000007 Mohamed Rizk 1 , Ali K. Attia 2, 3 , Heba Y. Mohamed 2 , Mona S. Elshahed 1
Electroanalysis ( IF 2.7 ) Pub Date : 2020-04-08 , DOI: 10.1002/elan.202000007 Mohamed Rizk 1 , Ali K. Attia 2, 3 , Heba Y. Mohamed 2 , Mona S. Elshahed 1
Affiliation
|
A cobalt oxide nanoparticles (Co3O4NPs) and multi walled carbon nanotubes (MWCNTs) modified carbon paste electrodes were used to study the electrochemical behavior of linagliptin and empagliflozin in Britton Robinson buffer solution of pH 8.0 using cyclic and square wave voltammetry. The above mentioned modified electrodes showed highly sensitive sensing and gave an excellent anodic response for both drugs. The peak current varied linearly over the concentration ranges: 3.98×10−5–1.53×10−3 mol L−1 (18.82–723.00 μg/mL) and 7.94×10−6–1.07×10−4 mol L−1 (3.65–48.25 μg/mL) with determination coefficients of 0.9999 and 0.9998 for linagliptin and empagliflozin, respectively. The recoveries and relative standard deviations were found in the following ranges: 98.80 %–102.00 % and 0.23 %–1.90 % for linagliptin and 98.30 %–101.80 % and 0.11 %–1.86 % for empagliflozin. The detection and quantification limits were 1.13×10−5 and 3.76×10−5 mol L−1 (5.34and17.77 μg/mL) for linagliptin, 1.71×10−6and 5.68×10−6 mol L−1 (0.77 and 2.56 μg/mL) for empagliflozin. The proposed sensors have been successfully applied for the determination of the drugs in bulk, pharmaceutical formulations and biological fluids.
中文翻译：
验证伏安法同时测定散装，药物剂型和生物液体中的抗糖尿病药，利格列汀和依格列净
用氧化钴纳米颗粒（Co 3 O 4 NPs）和多壁碳纳米管（MWCNTs）修饰的碳糊电极，通过循环和方波伏安法研究了利格列汀和依帕列净在pH 8.0的Britton Robinson缓冲溶液中的电化学行为。上面提到的修饰电极对两种药物均表现出高度敏感的感应并具有出色的阳极反应。峰值电流在以下浓度范围内线性变化：3.98×10 -5 –1.53×10 -3 mol L -1（18.82–723.00μg/ mL）和7.94×10 -6 –1.07×10 -4 mol L -1（3.65–48.25μg/ mL），对利拉列汀和依帕格列净的测定系数分别为0.9999和0.9998。回收率和相对标准偏差在以下范围内：利格列汀为98.80％–102.00％和0.23％–1.90％，依帕列净为98.30％–101.80％和0.11％–1.86％。利格列汀的检出限和定量限分别为1.13×10 -5和3.76×10 -5 mol L -1（5.34和17.77μg/ mL），1.71×10 -6和5.68×10 -6 mol L -1（0.77和依帕格列净的2.56μg/ mL）。所提出的传感器已成功地用于确定散装药物，药物制剂和生物液体中的药物。
更新日期：2020-04-08
中文翻译：
验证伏安法同时测定散装，药物剂型和生物液体中的抗糖尿病药，利格列汀和依格列净
用氧化钴纳米颗粒（Co 3 O 4 NPs）和多壁碳纳米管（MWCNTs）修饰的碳糊电极，通过循环和方波伏安法研究了利格列汀和依帕列净在pH 8.0的Britton Robinson缓冲溶液中的电化学行为。上面提到的修饰电极对两种药物均表现出高度敏感的感应并具有出色的阳极反应。峰值电流在以下浓度范围内线性变化：3.98×10 -5 –1.53×10 -3 mol L -1（18.82–723.00μg/ mL）和7.94×10 -6 –1.07×10 -4 mol L -1（3.65–48.25μg/ mL），对利拉列汀和依帕格列净的测定系数分别为0.9999和0.9998。回收率和相对标准偏差在以下范围内：利格列汀为98.80％–102.00％和0.23％–1.90％，依帕列净为98.30％–101.80％和0.11％–1.86％。利格列汀的检出限和定量限分别为1.13×10 -5和3.76×10 -5 mol L -1（5.34和17.77μg/ mL），1.71×10 -6和5.68×10 -6 mol L -1（0.77和依帕格列净的2.56μg/ mL）。所提出的传感器已成功地用于确定散装药物，药物制剂和生物液体中的药物。
京公网安备 11010802027423号